Sensex Rises Over 400 Points; Nifty At 24,750

Indian shares closed higher Thursday, with the S&P/BSE Sensex up 0.55% and the NSE Nifty rising 0.53%, driven by expectations of U.S. Federal Reserve rate cuts following weak economic data and anticipation of a 25 basis point rate cut by the Reserve Bank of India on June 6. Dr. Reddy's Laboratories notably surged 3.1% after announcing a collaboration with Alvotech to develop a biosimilar version of Keytruda.

Analysis

Indian equity markets demonstrated resilience, concluding Thursday's session with modest gains, as the S&P/BSE Sensex advanced 0.55% to 81,442.04 and the NSE Nifty index rose 0.53% to 24,750.90. This upward movement, reflecting a moderately positive market sentiment (score 0.5) and an optimistic tone, was primarily fueled by heightened speculation of at least two U.S. Federal Reserve interest rate cuts this year, following weaker-than-expected U.S. private payrolls and services data. Domestically, anticipation is building for the Reserve Bank of India's monetary policy decision on June 6, with widespread expectations for a third consecutive 25 basis point rate cut. The positive market breadth on the BSE, with 2,272 shares advancing against 1,705 declining, was further supported by gains across other Asian markets, a softer U.S. dollar, and lower U.S. Treasury yields. Notably, Dr. Reddy's Laboratories (RDY) surged 3.1%, reflecting strong positive sentiment (ticker sentiment 0.7), after announcing a strategic collaboration with Alvotech (ALVO, ticker sentiment 0.6) to co-develop, manufacture, and commercialize a biosimilar version of Keytruda. Other significant contributors to the rally included ICICI Bank (IBN), Sun Pharma, Adani Ports, UltraTech Cement, Reliance Industries, and Power Grid Corp, all posting gains between 1-2%.

Key Decisions for Investors

• Investors should closely monitor the Reserve Bank of India's monetary policy decision on June 6; an anticipated 25 basis point rate cut could further bolster market sentiment and liquidity, particularly benefiting rate-sensitive sectors.
• The strategic collaboration between Dr. Reddy's Laboratories (RDY) and Alvotech (ALVO) for a Keytruda biosimilar presents a significant catalyst; the 3.1% surge in RDY stock warrants attention for potential further upside.
• Given that current market optimism is substantially linked to expectations of monetary easing in both the U.S. and India, investors should assess portfolio exposure to shifts in U.S. economic data or central bank forward guidance which could alter these rate cut probabilities.